A phase II trial of crenolanib plus chemotherapy in newly diagnosed FLT3-mutated AML demonstrated a high CR rate of 85%; notably, 70% of patients remained alive and disease free with a median follow-up of 29.3 months (55). The gene discussed is FLT3; the disease is acute myeloid leukemia.